It is disheartening, though not surprising, to read stories involving crooked behavior by pharma companies.
In an announcement Thursday by prosecutors in Philadelphia, the company agreed to forfeit $185 million. It also will pay $237.5 million to resolve civil liabilities over off-label marketing of Trileptal and for paying kickbacks to health care providers in a bid to get them to prescribe that and other drugs.
The Swiss company is the world's third-biggest drug maker by revenue."
No comments:
Post a Comment